The mortality rate due to idiopathic pulmonary fibrosis (IPF) increased from 1979 to 2016 in the United Kingdom, a retrospective analysis shows. Researchers estimate that death due to IPF is close to 7% annually among respiratory diseases, pointing to approximately 5,500 people dying from the disease in the U.K.
News
NP-120 (ifenprodil), an oral small molecule being repurposed by Algernon Pharmaceuticals for the treatment of idiopathic pulmonary fibrosis (IPF), has shown promise in preclinical studies and may soon enter Phase 2 clinical tests, the company announced. Originally developed in the 1990s and sold under the brand name…
Screening newborns for genetic diseases with treatments that can prevent crippling or deadly progression, especially for rare disorders, has a ways to go in the United States. No state today tests for all 35 disorders recommended under a federal screening panel, and even in those that come close, rare…
Oklahoma suffers more tornadoes than any other state, has the highest per-capita rate of women in U.S. prisons, ranks second in the number of teen births per 100,000 teenage girls, and has the nation’s third-highest rate of uninsured residents — with 13.9% of all Oklahomans lacking health coverage. As if…
A new clinical model for terminal idiopathic pulmonary fibrosis (IPF) that allows patients to receive treatment at home has increased patient satisfaction, decreased hospital deaths, led to better symptom management, and lowered healthcare costs. Those outcomes of this new clinical model were published recently in the journal NEJM…
The Pulmonary Fibrosis Foundation (PFF) announced that its nationwide Care Center Network (CCN) now encompasses 68 medical centers in 33 states, following the addition of eight sites with recognized expertise in pulmonary fibrosis (PF) diagnosis, treatment,…
A patient with idiopathic pulmonary fibrosis (IPF), enrolled in the ZEPHYRUS Phase 3 clinical study, has been dosed with FibroGen’s investigational therapy pamrevlumab, the company announced. Still recruiting participants, the ZEPHYRUS study (NCT03955146) is expected to enroll approximately 565 IPF patients who have not responded to,…
Increased activity of certain matrix metalloproteinases (MMPs), enzymes that regulate cell behavior, may explain the risk for developing aggressive pulmonary fibrosis in people with Hermansky-Pudlak syndrome (HPS), a rare genetic disorder, according to new research. The study highlights MMP-2 and MMP-9. The findings suggest that these unique…
Low levels of an enzyme associated with the rare childhood disorder sialidosis may lead to the development of idiopathic pulmonary fibrosis (IPF), according to new research. The findings also suggest that NEU1 enzyme levels may help in determining fibrosis’ risk and likely prognosis. The study “…
Boehringer Ingelheim will add Bridge Biotherapeutics’ experimental inhibitor BBT-877 to its portfolio of potential therapies for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). This follows the completion of a collaboration and global license agreement between the two companies for the development of BBT-877 for…
